Lindley A Barbee1,2, Matthew R Golden1,2,3. 1. Division of Infectious Diseases, Department of Medicine, University of Washington, 325 9th Ave, Box 359777, Seattle, WA 98104, USA. 2. Public Health - Seattle & King County HIV/STD Program, Seattle, WA, 325 9th Ave, Box 359777, Seattle, WA 98104, USA. 3. Department of Epidemiology, University of Washington, Seattle, WA, 325 9th Ave, Box 359777, Seattle, WA 98104, USA.
Abstract
BACKGROUND: Ceftriaxone is the only consistently active antimicrobial agent recommended for the treatment of Neisseria gonorrhoeae. Although some new antimicrobials are in development, the necessity to expand treatment options in the near term may require using older drugs that have not been widely used to treat gonorrhoea. METHODS: We conducted a literature review of clinical trials and case series, published from 1983 to 2017, reporting treatment efficacy results following administration of 1 g aztreonam intramuscularly or IV for uncomplicated gonococcal infections. We summed trial data, stratified by anatomical site of infection, and calculated summary efficacy estimates and 95% CI for each site of infection. RESULTS: The 10 identified clinical trials enrolled 678, 38 and 16 individuals with urogenital, rectal and pharyngeal gonorrhoea, respectively. Aztreonam had an efficacy of 98.6% (95% CI: 97.5%-99.4%) for urogenital, 94.7% (95% CI: 82.3%-99.4%) for rectal and 81.3% (95% CI: 54.4%-96.0%) for pharyngeal gonococcal infections. CONCLUSIONS: Although most clinical trials included in this meta-analysis were conducted >30 years ago, aztreonam appears to have excellent efficacy for urogenital gonorrhoea; its efficacy at extragenital sites remains uncertain.
BACKGROUND:Ceftriaxone is the only consistently active antimicrobial agent recommended for the treatment of Neisseria gonorrhoeae. Although some new antimicrobials are in development, the necessity to expand treatment options in the near term may require using older drugs that have not been widely used to treat gonorrhoea. METHODS: We conducted a literature review of clinical trials and case series, published from 1983 to 2017, reporting treatment efficacy results following administration of 1 g aztreonam intramuscularly or IV for uncomplicated gonococcal infections. We summed trial data, stratified by anatomical site of infection, and calculated summary efficacy estimates and 95% CI for each site of infection. RESULTS: The 10 identified clinical trials enrolled 678, 38 and 16 individuals with urogenital, rectal and pharyngeal gonorrhoea, respectively. Aztreonam had an efficacy of 98.6% (95% CI: 97.5%-99.4%) for urogenital, 94.7% (95% CI: 82.3%-99.4%) for rectal and 81.3% (95% CI: 54.4%-96.0%) for pharyngeal gonococcal infections. CONCLUSIONS: Although most clinical trials included in this meta-analysis were conducted >30 years ago, aztreonam appears to have excellent efficacy for urogenital gonorrhoea; its efficacy at extragenital sites remains uncertain.
Authors: Marcus Y Chen; Anna McNulty; Ann Avery; David Whiley; Sepehr N Tabrizi; Dwight Hardy; Anita F Das; Ashley Nenninger; Christopher K Fairley; Jane S Hocking; Catriona S Bradshaw; Basil Donovan; Benjamin P Howden; David Oldach Journal: Lancet Infect Dis Date: 2019-06-10 Impact factor: 25.071
Authors: David W Eyre; Nicholas D Sanderson; Emily Lord; Natasha Regisford-Reimmer; Kevin Chau; Leanne Barker; Markus Morgan; Robert Newnham; Daniel Golparian; Magnus Unemo; Derrick W Crook; Tim Ea Peto; Gwenda Hughes; Michelle J Cole; Helen Fifer; Anne Edwards; Monique I Andersson Journal: Euro Surveill Date: 2018-07
Authors: Stephanie N Taylor; David H Morris; Ann K Avery; Kimberly A Workowski; Byron E Batteiger; Courtney A Tiffany; Caroline R Perry; Aparna Raychaudhuri; Nicole E Scangarella-Oman; Mohammad Hossain; Etienne F Dumont Journal: Clin Infect Dis Date: 2018-08-01 Impact factor: 9.079
Authors: Lindley A Barbee; Olusegun O Soge; Negusse Ocbamichael; Angela LeClair; Matthew R Golden Journal: Antimicrob Agents Chemother Date: 2020-12-16 Impact factor: 5.191